With increasing legalization and societal acceptability, cannabis use is increasingly prevalent. To date, 39 US states have legalized cannabis for either medical and/or recreational use, and this number is growing. The consequences of cannabis use are not yet fully understood, but available data indicate that while occasional cannabis use may offer analgesic benefit for some individuals, others struggle with adverse effects such as cannabis use disorder (CUD), cannabinoid hyperemesis, or incident or emerging psychosis. Certain patient populations are uniquely susceptible to cannabis use and/or its negative consequences. People with mental illness are significantly more likely to use cannabis and develop CUD. Furthermore, certain racial/ethnic minoritized populations are at a higher risk of co-use of cannabis and tobacco as well as exclusive cannabis use. Youth and adolescents are another priority population at high risk for both cannabis use and negative associated consequences over the lifespan. In an era of increasing legalization, Addiction Psychiatrists must be knowledgeable about and attuned to clinical implications of policy changes, individual patient risk factors, and treatment methods for problematic cannabis use. This symposium will present epidemiologic data, policy-to-practice implications, and cutting-edge evidence-based treatments for cannabis use disorder in priority populations such as people with psychiatric illness, racial/ethnic minoritized populations, and youth.